The in vitro activity of piperacillin, a new semisynthetic piperazine penicillin derivative, was evaluated against 626 clinical isolates and compared with the activity of other ,-lactam antibiotics. At a concentration of 0.1 pg/ml, piperacillin inhibited all streptococci except enterococci. Non-f,-lactamase-producing staphylococci were inhibited by 1.6 pg or less per ml. Both f6-lactamase-and non-,8-lactamase-producing Haemophilus were inhibited by 0.1 ,ug/ml. Piperacillin inhibited non-,-lactamase-producing Escerichia coli, Salmonella, and Shigella at a concentration of 6.3 pg/ml, The superior clinical efficacy of,B-lactam compounds, as well as the toxicity inherent in the use of 2-deoxystreptamine derivatives such as gentamicin or tobramycin, has prompted a continuing search for penicillins with greater in vitro activity. Carbenicillin has proved highly successful in the treatment oflife-threatening infections in patients with compromised host defenses, and recently ticarcillin has been shown to have activity equal or superior to that of carbenicillin (3, 7, 8) . However, the activity of both of these compounds against Kiebsiella and many members of the Enterobacteriaceae is poor. Furthennore, the large concentrations of these drugs used in treatment of infection require delivery of a large sodium load that can result in toxic reactions of bleeding and hypokalemic alkalosis (4). Piperacllin (Fig. 1) 
pounds, as well as the toxicity inherent in the use of 2-deoxystreptamine derivatives such as gentamicin or tobramycin, has prompted a continuing search for penicillins with greater in vitro activity. Carbenicillin has proved highly successful in the treatment oflife-threatening infections in patients with compromised host defenses, and recently ticarcillin has been shown to have activity equal or superior to that of carbenicillin (3, 7, 8) . However, the activity of both of these compounds against Kiebsiella and many members of the Enterobacteriaceae is poor. Furthennore, the large concentrations of these drugs used in treatment of infection require delivery of a large sodium load that can result in toxic reactions of bleeding and hypokalemic alkalosis (4) . Piperacllin ( Fig. 1) is a new piperazine penicillin derivative which preliminary observations have indicated may have greater activity than drugs heretofore available to treat enterobacterial, Pseudomonas, and anaerobic infections.
These factors prompted us to evaluate the in vitro activity of piperacillin in comparison with penicillins and cephalosporins in use or under study. We also attempted to determine the susceptibility of piperacillin to ,-lactamase hydrolysis to determine whether its increased activity could be related to ,B-lactamase stability, and to assess its synergistic activity with aoglycosides and one of the cephalosporins, cefazolin. sputum of patients hospitalized at Columbia-Presbyterian Medical Center, but isolates from earlier studies in which particular resistance mechanisms were known to be present were also used. All organisms tested represented single isolates, and nosocomial-outbreak strains were specifically excluded.
Susceptibility tests. The minimum inhibitory concentration (MIC) was determined in both broth and agar, utilizing a replicating device. More detailed descriptions have been published elsewhere (1) . The standard inoculum used was 105 organisms (colonyforming units [CFU]) unless otherwise specified. The minimum bactericidal concentration (MBC) was determined by plating 0.01 ml from clear tubes in an MIC determination to Mueller-Hinton agar containing 5% sheep blood. The MBC was the concentration at which there were fewer than five colonies after 24 h of incubation.
Killing curves were derived from experiments conducted in broth with exponentially growing cells in the MIC or in a designated concentration. Samples were removed from a gyratory shaker, immediately diluted, and plated as previously described (2) .
8-lactamase assays. Partially purified /B-lactamases and crude extracts were used. Both the microiodometric assay and a spectrophotometric assay were used (6, 9) . Synergy study. Synergy was measured by the agar dilution, checkerboard isobologram, and killing-curve techniques as described previously (2) . Synergy was considered to be present when there was a fourfold decream in the MICs of both agents or a two-log decrease in CFU in a killing experiment. Partial synergy was defined as a fourfold decrease in the MIC of one compound.
RESULTS
Antibacterial activity. The overall antibacterial activity of piperacillin against gram-positive and gram-negative aerobic and anaerobic species is given in Table 1 . Piperacillin inhibited the majority (97%) of /3-hemolytic streptococci, S. pyogenes (group A), and S. agalactiae (group B) at 0.2 jig/ml and inhibited S. pneumoniae isolates at 0.1 ,g/ml. Piperacillin inhibited 58% of S. faecalis at 0.4 ,ug/ml and 100% at 1.6 Ag/ml.
The activity against staphylococci, both S. epidermidis and S. aureus, was related to the presence of /8-lactamases. Isolates lacking ,B-lactamases had MICs of 1.6 ,ug/ml or less. ,B-Lactamase-producing isolates had MICs between 3.1 and 400 ug/ml. Haemophilus influenzae and H. parainfluenzae were inhibited by 0.1 ug or less per ml as well. Isolates of N. gonorrhoeae, including,8-lactamase-producing isolates, were inhibited by less than 0.1 jig/ml.
All of the Enterobacteriaceae were hospital isolates. This qualification is necessary to explain the activity of the drug shown in Table 1 .
Escherichia coli that lacked ,8-lactamases were inhibited by 6.3 ug or less per ml. The MICs of piperacillin for E. coli containing type III /3-lactamases were 100 to 800 ,ug/ml. Salmonella and Shigella strains that lacked /-lactamases were inhibited by 6.3 ,ug or less per ml, whereas concentrations in excess of 200 ug/ml were needed to inhibit strains that had ,8-lactamase activity. Strains of Proteus mirabilis were inhibited by low concentrations, 0.8 jig/ml. Other Proteus species and Providencia varied in their susceptibility; half of the isolates were inhibited by 50 ug/ml, whereas the MICs for remainder were 200 ,ug/ml. Only 50% of Klebsiella pneumoniae were inhibited by 12.5 ug/ml, whereas 84% of Enterobacter (E. cloacae and E. aerogenes) were inhibited by the same concentration. Serratia, except for pigmented isolates, were resistant to piperacillin since only 47% were inhibited by 100 ug/ml. Citrobacter were susceptible, with 76% inhibited by 6.3 Ag/ml. Piperacillin inhibited 57% ofPseudomonas aeruginosa at a concentration of 3.1 /Lg/ml and 95% at 25 pg/mL Piperacillin inhibited 78% of Bacteroides fragilis at 25 ,ug/ml. Peptococcus and Peptostreptococcus were inhibited by less than 3.1 jg/mL, as were Fusobacterium. Table 3 . Serratia marcescens showed a difference between MICs and MBCs. The effect of pH on the activity of piperacillin against most of the Enterobacteriaceae was minimal. In general, the antibacterial activity in a basic medium was less than that in acidic medium. The activity of piperacillin against Pseudomonas was pH dependent (Fig.  2) . At pH 6 and a concentration of 25 yg/ml, piperacillin inhibited 100% of the organisms, whereas at pH 7 100% of the isolates were inhibited at 100 ,ug/ml, and at pH 8 At 12.5 pg/ml, piperacillin inhibited 92% of Pseudomonas aeruginosa compared with 16% inhibited by carbenicillin, 38% inhibited by ticarcillin, 30% inhibited by mezlocillin, and 85% ;nhibited by azlocillin. The activity of piperacillin was similar to that of gentamicin against ) and with amikacin against P. aeruginosa 271 (4) and Serratia 2957 PO).
Pseudomonas. At 25 ,ug/ml, piperacillin an mezlocillin inhibited 78 to 81% of Bacteroide compared with only 26% inhibited at that lev4 by carbenicillin and ticarcillin. Table 5 illustrates the comparative activity c carbenicillin, mezlocillin, and piperacillin agairs Staphylococcus aureus, S. epidermidis, enterc cocci (Streptococcus faecalis, S. faecium), an ,B-hemolytic streptococci (groups A, X, G, an F). Ampicillin was slightly more active againu the /8-hemolytic streptococci than were the othe compounds, and piperacillin offered no improv4 ment in activity over carbenicillin. In contras piperacillin was much more active against ente: ococci than was carbenicillin. (Fig. 5) against P. aeruginosa. 11 More than a two-log decrease in CFU was demonstrated after 4 and 24 h of incubation in the presence of piperacillin and amikacin.
Id Similar to other penicillins, particularly the anti-Pseudomonas penicillins, piperacillin showed excellent synergistic activity when combined with aminoglycosides (1, 5) . Of particular note was the synergy of amikacin and piperacillin against Serratia, which is a hospital pathogen of increasing importance. Our results indicate, however, that synergy of piperacillin and an aminoglycoside against Klebsiella is less likely to occur than against Pseudomonas.
Although no antagonistic activity was observed with piperacillin-aminoglycoside combinations tested here, piperacillin showed antagonistic activity when combined with cefazolin.
The clinical implication of synergistic or antagonistic activity of piperacillin should be evaluated further in vivo. In view of these in vitro results, it seems of value to have further animal and human studies with this compound to determine whether it could be used in lower concentrations than carbenicillin and thus avoid some of the adverse reactions encountered with high-dose carbenicillin therapy.
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